Clinical trial

The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

NCT04640870

Study summary

ClinicalTrials.gov

The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With Afatinib

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Afatinib Normalized identity: afatinib View linked drug · Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2015-03-15

PhaseN/A

Conditions

Non Small Cell Lung Cancerunresolved

EGF-R Positive Non-Small Cell Lung Cancerunresolved

EGFR Gene Mutationunresolved

Interventions

AfatinibDRUG · verified · RxNorm: afatinib

Sponsors & collaborators

Hellenic Cooperative Oncology Grouplead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04640870 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.